PHVS (Pharvaris NV) ROCE %: -69.15% (As of Mar. 2026)


PHVS Pharvaris NV PHVS
22 GF Score
Price $35.02
! 3 Warning Signs
View Full Analysis

What is Pharvaris NV ROCE %?

Pharvaris NV PHVS -2.39% 22 ROCE % is -69.15% as of Mar. 2026. GuruFocus rates PHVS with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Pharvaris NV's annualized ROCE % for the quarter that ended in Mar. 2026 was -69.15%.

Pharvaris NV  (NAS:PHVS) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Pharvaris NV ROCE % Related Terms

Pharvaris NV ROCE % Historical Data

* Premium members only.

The historical data trend for Pharvaris NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharvaris NV ROCE % Chart

Pharvaris NV Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -35.13 -47.09 -36.62 -43.59 -66.35

Pharvaris NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -69.46 -81.45 -64.20 -65.06 -69.15
PHVS
22GF Score
Pharvaris NV PHVS
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharvaris NV ROCE % Calculation

Pharvaris NV's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-198.856/( ( (305.105 - 24.058) + (352.992 - 34.665) )/ 2 )
=-198.856/( (281.047+318.327)/ 2 )
=-198.856/299.687
=-66.35 %

Pharvaris NV's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-204.728/( ( (352.992 - 34.665) + (300.333 - 26.501) )/ 2 )
=-204.728/( ( 318.327 + 273.832 )/ 2 )
=-204.728/296.0795
=-69.15 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -69.15% mean?
Pharvaris NV (PHVS) has a ROCE % of -69.15% as of Mar. 2026.
Is Pharvaris NV's ROCE % too high?
Pharvaris NV's current ROCE % is -69.15%. Overall, Pharvaris NV has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Pharvaris NV's ROCE % compare to BHVN and NRIX?
Pharvaris NV's ROCE % of -69.15% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Pharvaris NV's current ROCE % is -69.15%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharvaris NV stock overvalued right now?
Pharvaris NV (PHVS) has a current ROCE % of -69.15%. The current ROCE % is -69.15%. Pharvaris NV's overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Pharvaris NV (PHVS), the current ROCE % is -69.15% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Pharvaris NV Business Description

Other Exchanges 9EN:Germany
Address Emmy Noetherweg 2, Leiden, NLD, 2333 BK
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.
22GF Score

Get the complete analysis for PHVS

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.02
Price